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Background: Animal model studies revealed that the application of 1-methyltryptophan
(1-MT), a tryptophan (TRP) analog, surprisingly increased plasma levels of the TRP
metabolite, kynurenic acid (KYNA). Under inflammatory conditions, KYNA has been
shown to mediate various immunomodulatory effects. Therefore, the present study aims
to confirm and clarify the effects of 1-MT on TRPmetabolism inmice as well as in humans.
Methods: Splenocytes from Balb/C or indoleamine 2,3-dioxygenase knockout
(IDO1−/−) mice or whole human blood were stimulated with 1-MT for 6, 24,
or 36 h. C57BL/6 mice received 1-MT in drinking water for 5 days. Cell-free
supernatants and plasma were analyzed for TRP and its metabolites by tandem mass
spectrometry (MS/MS).
Results: 1-MT treatment induced an increase in TRP and its metabolite, KYNA in
Balb/C, IDO−/− mice, and in human blood. Concurrently, the intermediate metabolite
kynurenine (KYN), as well as the KYN/TRP ratio, were reduced after 1-MT treatment.
The effects of 1-MT on TRP metabolites were similar after the in vivo application of 1-MT
to C57BL/6 mice.
Conclusions: The data indicate that 1-MT induced an increase of KYNA ex vivo and in
vivo confirming previously described results. Furthermore, the results of IDO−/− mice
indicate that this effect seems not to be mediated by IDO1. Due to the proven
immunomodulatory properties of KYNA, a shift toward this branch of the kynurenine
pathway (KP) may be one potential mode of action by 1-MT and should be considered
for further applications.
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INTRODUCTION
1-methyltryptophan (1-MT) is a TRP analog described first in 1991 (1) as a potential competitive
inhibitor of the enzyme indoleamine 2,3-dioxygenase (IDO1). IDO1 is one rate-limiting enzyme of
the kynurenine pathway (KP) (Figure 1), which plays a crucial role in the regulation of the immune
response, notably as a counter-regulatory mechanism in the context of inflammation (2, 3). In
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FIGURE 1 | Main pathways of TRP degradation, including relevant enzymes [modified after (2, 3)]. Black arrows mark enzymatic reactions and dashed arrows include
more than one catalytic reaction step. Metabolites analyzed in this study are shaded gray. The catabolism of TRP by the enzymes TDO, IDO1/IDO2 represents the
rate-limiting step of the kynurenine pathway in which 95% of dietary TRP is oxidized. One percentage of dietary tryptophan for the synthesis of serotonin. Apart from
neuromodulatory properties (not shown), KYNA is an agonist of the broadly expressed receptors GPR35 and AhR. Furthermore, KYNA functions as an ROS
scavenger. KYNA production. In addition to the presented canonical pathway of KYNA formation, alternative routes of KYNA production, promoted by the presence of
ROS, are described (4). AADC, aromatic L-amino acid decarboxylase; AANAT, N-acetyltransferase; AhR, hydrocarbon receptor; AMO, anthranilate
3-monooxygenase; FOR, formamidase; GPR35: G-protein-coupled receptor 35; HAAO, 3-hydroxyanthranilic acid oxidase; HADO, 3-hydroxyanthranilic acid
3,4-dioxygenase; IDO, indolamine 2,3-dioxygenase; KAT, kynurenine aminotransferase; KMO, kynurenine 3-monooxygenase; KYNU, kynureninase; TDO, tryptophan
2,3-dioxygenase; TPH, tryptophan hydroxylase; ROS, reactive oxygen species.
cell free assays, it has been shown that 1-MT binds to the ferrous
IDO complex but cannot be catalytically converted to kynurenine
due to the additional methyl group (1). 1-MT is known for
its low toxicity and great pharmacokinetic properties such as
good intestinal absorption, low clearance, and low binding
to plasmatic proteins (5, 6). Two stereoisomers of 1-MT, 1-
methyl-D-tryptophan (D-1-MT also known as Indoximod) and
1-methyl-L-tryptophan (L-1-MT) are well studied and potential
inhibitors of IDO. Indoximod is under investigation in several
clinical trials (7–9) while L-1-MT or the combination of both
isoforms DL-1-MT is used as IDO inhibitors in preclinical
studies in vivo and in vitro (10–12). According to the reported
IC50 values of L-1-MT (120µM) and D-1-MT (2.5mM) in
HeLa cells (13), it is currently assumed that both L- and
D-1-MT are weak IDO inhibitors in vivo (14, 15). Indeed,
the D-isomer completely fails to inhibit the enzyme activity
in inflammatory stimulated HeLa cells (9). The lack of IDO
inhibition might be due to a low affinity of the inhibitor to the
enzyme concurrent with a physiologically limited accumulation
of the inhibitor to serum levels similar to those of TRP (16).
Nevertheless, significant effects of these drugs on immune
response were reported in vivo and in vitro (2, 16) revealing
modes of actions other than IDO1 inhibition. Unexpectedly,
the oral or subcutaneous applications of 1-MT in Balb/C mice
(10) and pigs (11), resulted in increased plasma levels of the
TRP metabolite kynurenic acid (KYNA), a stable end product
of KP, rather than KYN, which is an intermediate metabolite
of KP. Due to the proven immunomodulatory properties of
KYNA (3), a shift of KP toward the KYNA branch may be one
potential mode of action by 1-MT, which may also be relevant
for the application in humans. As previously described in detail
(3), under inflammatory conditions, KYNA mediates mainly
immunosuppressive effects, notably by targeting the G-protein-
coupled receptor 35 (GPR35)- or aryl hydrocarbon receptor
(AhR)-associated signaling pathways (2, 17, 18). For instance,
KYNA reduces the expression and secretion of TNFα (10, 19–
21) and diminishes the secretion of high-mobility group box
1 in monocytes (20, 22). Furthermore, there is evidence that
KYNA induces downregulation of IL23/IL17 axis (23), which
is assumed to have beneficial effects as an anti-inflammatory
treatment in many immune-mediated diseases (24). The anti-
inflammatory effects of KYNA, as frequently observed in in
vitro models, are also confirmed in vivo in mice. It has been
shown that, in a mouse model of LPS-induced septic shock,
KYNA treatment attenuated LPS induced pro-inflammatory
mediators such as TNF-α and nitric oxide (NO) and significantly
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rescued animals from LPS-induced death (22, 25). It has been
reported that the application of 1-MT in pigs resulted in
increased plasma levels of KYNA of around 5µM (11) which
is sufficient to activate AhR and GPR35 as KYNA has a
great affinity to the latter even at low micromolar range. In
addition, these observations are further supported ex vivo in
murine immune cells. Treatment of murine splenocytes with
5µM KYNA exerted a slight proliferative effect concurrent with
increased secretion of IL-1β and IL-6 (26), suggesting that 1-
MT mediates its biological and yet significant effects via AhR
and/or GPR35.
Taking the observed effects of 1-MT on KYNA production
into consideration, the present study aimed at verifying these
effects in other mouse strains as well as in humans. Furthermore,
additional insights on other TRP metabolites are provided. We
treated animals and/or human blood with 1-MT for different
times. To further investigate if KYNA production is related to the
activity of the IDO enzyme, the effect of 1-MT in IDO knockout
mice was examined. In addition to ex vivo experiments, 1-MT
was applied in vivo in the C57BL/6 mice to verify the previously
described effects of 1-MT in Balb/C mice (10). TRP metabolism
in cell culture supernatants or plasma was characterized by the
metabolites of TRP and its downstream metabolites kynurenine
(KYN), quinolinic acid (QUIN), KYNA, and serotonin (5-HT).
As a marker for increased IDO1 activity, the ratio of KYN to TRP
was calculated.
MATERIALS AND METHODS
Animals
Female Balb/C (n = 6), IDO1−/−, and C57BL/6 mice (n = 41)
were maintained in the breeding facility at the University of
Greifswald, Germany. IDO1−/− mice with a Balb/C background
(n = 6) were provided by M. Moser (Brussels, Belgium) with
the permission of A. Mellor (Augusta, Georgia, U.S.A.). As
described in detail (27), the IDO1−/− mice were generated using
a DNA construct that targets the murine IDO gene in embryonic
stem cells. The defective gene expression was verified in tissues
with a high level of constitutive IDO1 expression by PCR and
Western Blot. All mice were kept in groups (6–9 mice/cage)
under controlled conditions with 12/12 light/dark cycle and
access to food and water ad libitum. All animal experiments were
approved by the Animal Protection Committee of Mecklenburg-
Vorpommern, Germany (AZ 7221.3-1.1-083/12).
Experiment 1: Stimulation of Murine
Splenocytes and Human Whole Blood With
1-MT
Mice were euthanized as previously described (10). Spleens
were aseptically removed into sterile, cold RPMI 1640 medium
(Biochrom KG Berlin, Germany), and cell suspensions were
prepared within 1 h after harvesting the organ. For ex vivo
stimulation of whole blood cell cultures, human blood from
six individual healthy donors was obtained from the Institute
of Immunology and Transfusion Medicine, Greifswald after a
written consent for scientific use. 1-MT (L-isomer, purity 95%;
Sigma-Aldrich, Deisenhofen, Germany) was dissolved in 1N
NaOH to a stock concentration of 1M, and further dilutions
were made in RPMI medium to a final concentration of 600µM.
A NaOH solvent control was prepared by adding 1N NaOH
to the cell culture medium to the same volume as used for 1-
MT. After incubation with 1-MT for 6, 24, or 36 h. TRP and its
metabolites were analyzed in cell-free supernatants by tandem
mass spectrometry (MS/MS).
Experiment 2: in vivo 1-MT Administration
1-MT (DL-isomer, 2 mg/ml) was given to C57BL/6 mice (n
= 24) in the drinking water for 5 days. A control group (n
= 17) received drinking water without 1-MT. After treatment,
all animals were euthanized, blood was drawn by retroorbital
puncture as previously described (10) into EDTA-tubes, plasma
was separated and stored at −80◦C until analysis of TRP and
its metabolites.
Quantification of 1-MT and TRP
Metabolites
The determination of 1-MT, TRP, KYN, KYNA, and QUIN in
plasma or cell-free supernatants was performed as previously
described in detail (28, 29) using an API2000 tandem mass
spectrometer equipped with an electrospray ion source (ABSciex,
Darmstadt, Germany). As an indicator of IDO1 activation, the
ratio of KYN and TRP (KYN× 100/TRP) was calculated (30).
Statistics
Statistical analyses of experiment 1 was performed using SAS
software, version 9.4 (SAS Institute Inc., Cary, NC, USA). The
continuous response variables (TRP, KYN, KYNA, QUIN, 5-HT)
were analyzed by Analysis of Variance (ANOVA) comprising the
fixed effects treatment (1-MT, Control), and sampling time (6,
24, 36 h) and their interaction (treatment × time). In order to
compare the six sets of measurements, the data were analyzed
by fitting and testing generalized linear models applying the
GLIMMIX procedure. The repeated statement in the GLIMMIX
procedure was used with respect to repeated measurements
on the same subject. Tukey–Kramer procedure was used for
pair-wise multiple comparisons of TRP metabolites within one
species. For the presentation of the results, the least square means
(LS-means) and their standard errors (SE) were calculated and
tested for each fixed effect in the model using the Tukey–Kramer
procedure for all pair-wise comparisons. Data of experiment 2
were analyzed using the SigmaPlot 14.0 software. Differences
between the treatment and the control group were compared
withWelch’s t-test orMann-Whitney U test according to unequal
variances of the treatment and the control group or failure of
the normality test, respectively. The effects and differences were
considered significant at p < 0.05.
RESULTS
1-MT Modifies TRP Metabolism and
Increases KYNA ex vivo
To investigate whether 1-MT induces the production of KYNA
ex vivo, murine splenocytes and human blood were stimulated
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with 1-MT for either 6, 24, or 36 h according to the experimental
design 1. Due to the weak inhibitory potential of L-1-MT (IC50
= 120µM) (13), a relatively high concentration i.e., 600µM
L-1-MT was chosen to achieve effective inhibition of IDO.
To further investigate if KYNA production is dependent on a
functional IDO enzyme, the effect of 1-MT in IDO knockout
mice was examined. TRP and its metabolites were measured in
supernatants of cell culture.
Pair-wise comparisons between 1-MT treatment and controls
(main effect: Treatment) are presented in Table 1. Thereby,
the concentrations of TRP were increased by 1-MT in Balb/C
and IDO1−/− mice as well as in human blood. That does
not seem surprising since the applied L-1-MT contains 5% L-
TRP, which corresponds to a concentration of 30µM. In both
murine and human cell culture supernatants, the increased
level of TRP concentration corresponded to decreased levels of
KYN, and 5-HT indicating downregulation of TRP breakdown.
The downstream TRP metabolite QUIN was reduced by 1-MT
in mice but not in human blood, suggesting species-specific
differences. The observation of a diminished degradation of TRP
TABLE 1 | Pairwise comparisons of the treatment effect (1-MT vs. control) using
Tukey-Kramer test.
1-MT Control SE P-value
LSM LSM
TRP (µM)
Balb/C 250.94 227.44 3.24 0.003
IDO1−/− 221.61 202.00 4.43 0.030
Human 220.78 197.00 5.08 0.002
KYN (µM)
Balb/C 1.72 2.26 0.11 0.001
IDO1−/− 1.45 1.90 0.07 0.001
Human 1.62 2.34 0.18 0.001
KYNA (µM)
Balb/C 4.95 4.06 1.05 0.047
IDO1−/− 2.56 1.20 0.16 <0.001
Human 4.09 1.37 0.29 <0.001
QUIN (µM)
Balb/C 0.42 0.52 0.02 0.002
IDO1−/− 0.38 0.45 0.01 <0.001
Human 0.33 0.32 0.01 0.64
5-HT (µM)
Balb/C 1.20 1.37 0.03 <0.001
IDO1−/− 1.12 1.28 0.02 <0.001
Human 1.01 1.08 0.01 0.002
KYN/TRP ratio
Balb/C 0.69 1.00 0.06 0.001
IDO1−/− 0.66 0.94 0.03 <0.001
Human 0.73 1.22 0.12 0.002
Concentrations of the metabolites TRP, KYN, KYNA, QUIN, 5-HT were measured in
cell culture supernatants of isolated splencocytes (Balb/C, IDO1−/−) and human whole
blood cell culture. As marker for IDO activity KYN/TRP ratio was calculated. Results are
presented as LS-means (LSM) ± SE averaged over three incubation times (6, 24, 36 h)
per subject. 1-MT: n = 18 (six per species); Control: n = 18 (six per species).
P-values < 0.05 are marked in bold.
via KP was further supported by the results of KYN to TRP
ratio, often used as a marker for IDO activity (28). This ratio was
decreased by 1-MT at all time points both in mice and human
cell cultures, indicating that 1-MT inhibited the activity of IDO.
Despite the presumed IDO inhibition by the high concentrations
of 1-MT, the synthesis of kynurenine was not reduced completely,
indicating a lack of effective IDO inhibition. The treatment
effect on TRP and its metabolites KYN, 5-HT, and QUIN were
comparable between different times of incubation with 1-MT
(treatment× time, p > 0.05) (Figures 2A–C).
1-MT induced an increase of KYNA in cell culture
supernatants of murine splenocytes as well as in human blood,
confirming studies in pigs and mice (10, 11). Interestingly, this
effect was also detected in IDO1−/− mice, revealing that KYNA
production was not related to a functional IDO enzyme. In
splenocytes of IDO1−/− mice and human blood, increased levels
of KYNA were detected after 6, 24, and 36 h of stimulation with
1-MT, indicating a TRP breakdown toward the KYNA branch.
Interestingly, in Balb/C mice, KYNA levels were lower in the
treatment group compared to controls after 6 h of stimulation
with 1-MT (treatment × time, p < 0.05). However, this effect
might not reflect a reduced KYNA production but is rather
the consequence of an increased KYNA concentration in the
control group.
1-MT Modifies TRP Metabolism and
Increases KYNA in vivo
We next investigated whether 1-MT induces the production
of KYNA after in vivo application. According to the design of
experiment 2, 1-MT was given to C57BL/6 in drinking water
over a period of 5 days. Afterward, TRP and its metabolites
were measured in plasma. The results are presented in Figure 3.
After 5 days, 1-MT concentration in plasma was reached to
∼25.5µM, whereas in control animals the concentration was
below the detection range (LLOQ: <2.3µM) (data are not
shown). The ratio of KYN to TRP was decreased after 1-MT
treatment indicating a diminished TRP breakdown. However,
it is assumed that the plasma concentrations achieved in vivo
do not effectively block IDO activity, indicating that this effect
is not related to the activity of the IDO enzyme. Similar to ex
vivo findings, the pairwise comparisons reveal that the 1-MT
treatment increased plasma levels of TRP and KYNA. In contrast,
the concentrations of QUIN and 5-HT were not significantly
affected by 1-MT treatment.
Together with the previously published findings from mice
and pigs, the present study reveals that 1-MT induces an
increase of KYNA concentrations in different species, including
humans. Furthermore, these effects seem to be independent of
IDO activity.
DISCUSSION
In this study, effects of 1-MT on TRP metabolism were
investigated in mice and humans to provide additional insights
into potential modes of action of 1-MT as previously described
in mice and pigs (10, 11). The results of experiment 1 show
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FIGURE 2 | Effect of 1-MT on TRP metabolism in cultured splenocytes isolated from Balb/C mice (A), IDO−/− mice (B), and in human whole blood cell culture (C).
TRP and its metabolites KYN, KYNA, QUIN were measured in cell culture supernatants after 6, 24, or 36 h incubation with 1-MT (600µM) by MS/MS. KYN/TRP ratio
was calculated as a marker for IDO1 activity. The results are presented as LS-means + SE. Significant differences between the 1-MT and the control group were
calculated using the Tukey-Kramer test and are shown for each incubation time. n = 6 per species, *P < 0.05.
that 1-MT increased the concentrations of TRP in supernatants
of cultured murine splenocytes, human blood cell culture,
and murine plasma. These results confirm the data from pigs
where plasma concentrations of TRP are increased after 24 h of
treatment with 1-MT subcutaneously (11). The effect of increased
TRP concentrations may be a result of indirect supplementation
of TRP contained in commercially available 1-MT, though the
applied 1-MT has a purity of at least 95%. As confirmed by
previous studies, 1-MT contains ≤5% TRP (11, 31), which may
affect the results of in vitro or ex vivo studies, independently
of IDO activity. However, the indirect TRP supplementation
does not sufficiently explain the results in vivo because the
amount of TRP, contained in 1-MT is negligible compared to
the dietary derived TRP amounts, which are positively regulated
by tryptophan 2,3-dioxygenase (TDO) (mainly expressed in the
liver) to maintain the homeostasis of TRP (32). It has been
further described that both isomers of 1-MTmimic TRP (14, 33),
which may feign an amino acid oversupply and, therefore, may
reduce the uptake of endogenous TRP to somatic cells resulting
in increased TRP levels. Although it could not be clarified
conclusively whether TRP contamination of 1-MT and/or other
effects such as TRP mimetics caused the increase of TRP, the
summary of results from previous studies, including the present
study, indicate that it seems to be a general effect. Since higher
TRP concentrations lead to an activation of TDO, one can
assume that TRP supplementation may result in an accelerated
TRP degradation concurrent with increased production of TRP
downstream metabolites. For instance, in human glioblastoma
cells, the TRP contamination of 1-MT (L-isomer) resulted in
an increased production of KYN, indicating an accelerated
degradation of TRP via KP (31). This was supported by studies in
pigs where TRP supplementation resulted in an overall activation
of the KP as well as the 5-HT system (34). In contrast, the results
of our present study show that the 1-MT-induced elevation of
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FIGURE 3 | Effects of 1-MT application on plasma concentrations of TRP (A), KYN (B), KYNA (C), QUIN (D), 5-HT (E), and the calculated KYN/TRP ratio (F). 1-MT
was applied via drinking water for 5 days. Control animals received drinking water without 1-MT. TRP and its metabolites were measured using MS/MS. The KYN/TRP
ratio was used as a marker for IDO1 activity. The results are presented as boxplot including the median, the interquartile range, and the min and max values.
Significant differences between the 1-MT- and control groups were calculated using the Welsh’s test (B–F) or the Mann-Whitney U test (A). 1-MT: n = 24; MYR: n =
17; ***P < 0.001, **P < 0.01, *P < 0.05.
TRP, which was associated with increased production of KYNA
with a decrease of other TRP metabolites such as KYN or 5-
HT in mice as well as in human blood. Also, the ratio of
KYN to TRP, often used as a marker for IDO activity, was
decreased in all investigated species after both ex vivo and in
vivo application of 1-MT. In the present study, these results
reveal an enhanced degradation of TRP directed to one specific
branch of the KP (see also Figure 1) which not only seems to
be a consequence of increased TRP levels but is also related to
1-MT. Although in the present study, the effect of 1-MT on
KYN to TRP ratio seems to be uniform between ex vivo and in
vivo studies, the in vivo treatment of healthy Balb/C mice (10)
or pigs (11) did not significantly affect the KYN to TRP ratio
indicating species/strain-specific responses to 1-MT or effects of
the experimental design. Nevertheless, the results from mice and
pigs (10, 11) showed independently from each other that 1-MT
induced an increase of KYNA indicating that this effect is not
restricted to a specific animal model. Furthermore, the findings
in human blood indicate that this effect may be even relevant for
the application of 1-MT in humans.
The finding that 1-MT induced an elevation of KYNA, but not
the intermediate metabolite KYN, raises the question of whether
TRP is metabolized directly to KYNA rather than through
IDO activity. Computational modeling of data evaluated from a
previously reported study in pigs (11) reveals that it is more likely
that increased levels of TRP are directly degraded to KYNA (35).
It is assumed that the major production of KYNA is attributed
to kynurenine aminotransferases (KATs), enzymes with a broad
spectrum of substrates besides KYN. In vitro analysis show that
TRP is a substrate for the enzyme KAT II with a similar Km-value
as the substrate KYN (36). Interestingly, in the present study,
KYNA was also increased in IDO knockout mice, supporting
the hypothesis that this effect is not related to a functional IDO
enzyme. This is supported by the finding that increased KYNA
levels were also measured after in vivo application of 1-MT,
although the plasma concentrations of 1-MT (∼25µM) were too
low to inhibit IDO effectively.
The finding that other TRP metabolites of KP or serotonin
pathway are decreased, or unaffected indicates that the KYNA
production is not mediated by one of the rate-limiting enzymes
of KP (canonical pathway) but might be mediated by other
TRP degrading enzymes or non-enzymatically. According to
this hypothesis, alternative mechanisms of KYNA production
(4) might be involved. For instance, it was described that
enzymes such as the aromatic amino acid transaminase are
able to catalyze TRP to intermediate metabolites which serve
as KYNA precursors in the presence of reactive oxygen radicals
(ROS) (4).
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The theory that increased TRP may promote KYNA
production was tested in an additional experiment. Thereby,
the application of 5% TRP (contained in L-1-MT) induced
an increase of KYNA production 3 h after application but not
after longer incubation time, indicating that the additional TRP
is metabolized via the kynurenine pathway (data not shown).
However, the KYNA production by L- and D-1-MT was 2 to 3-
fold higher compared to L-TRP alone, which leads one to assume
that the TRP contamination is not an exclusive explanation for
the increased KYNA values. According to this, it is suggested that
other mechanisms might be involved in the increased production
of KYNA. Although there is currently a lack of data, it cannot
be ruled out that 1-MT itself is metabolized or transformed to
TRP or other TRP relatedmetabolites by a yet unknown pathway.
These questions remain to be clarified in further studies.
In the present study, it seems surprising that the loss
of functional IDO1 in the IDO KO mice has no effect on
the 1-MT-induced changes of TRP metabolites. These data
implicate that other tryptophan-catabolizing enzymes like IDO2
and tryptophan 2,3-dioxygenase (TDO) might compensate
for the lack of IDO1. This theory is supported by other
studies demonstrating that IDO1 deficiency does not affect
the inflammation in murine models of arthritis, pregnancy, or
bacterial infection (27, 37, 38).
CONCLUSIONS
The results from the present study indicate that the
administration of 1-MT induces a shift of KP toward the
branch of KYNA. This effect was shown independently in
two mice strains as well as in human blood. Furthermore,
the results from IDO knockout mice, as well as the decreased
levels of KYN in vivo, indicate that the 1-MT-induced increase
of KYNA seems not to be dependent on IDO1 activity. This
was confirmed by the in vivo results where 1-MT levels were
too low for an effective IDO1 inhibition; nevertheless, KYNA
was increased in plasma. The increase of KYNA may be one
potential mode of action by 1-MT and should be considered
for preclinical studies and therapeutic applications in humans.
Furthermore, the application of 1-MT might have therapeutic
implications as it may provide a method to increase KYNA while
preserving IDO1 activity. Due to its immunoregulatory role,
the inhibition of IDO1 may not be appropriate for different
therapeutic approaches.
DATA AVAILABILITY STATEMENT
The datasets generated for this study are available on request to
the corresponding author.
ETHICS STATEMENT
Ethical review and approval was not required for the study on
human participants in accordance with the local legislation
and institutional requirements. The patients/participants
provided their written informed consent to participate in
this study. All animal experiments were approved by the
Animal Protection Committee of Mecklenburg-Vorpommern,
Germany (AZ 7221.3-1.1-083/12).
AUTHOR CONTRIBUTIONS
GD conceived the project, designed and performed the
experiments, and analyzed MS data. GD and EW wrote
the manuscript. EW analyzed the data, created the figures,
and wrote the first draft of the manuscript. AL and CS
assisted with performing of the MS analysis and critically
revised the manuscript for important intellectual content. All
authors critically reviewed the manuscript and approved the
final version.
FUNDING
EW was supported by the Rostock University Medical Center
(UMR, FORUN 889021).
ACKNOWLEDGMENTS
The authors are grateful to ChristianManteuffel from the Leibniz
Institute for FarmAnimal Biology (FBN) for statistical consulting
and technical support with SAS software. The authors are also
thankful to Murthy N. Darisipudi from the Department of
Immunology of University Medicine Greifswald for supporting
the linguistic editing of the manuscript.
REFERENCES
1. Cady SG, Sono M. 1-Methyl-dl-tryptophan, β-(3-benzofuranyl)-
dl-alanine (the oxygen analog of tryptophan), and β-[3-benzo
(b) thienyl]-dl-alanine (the sulfur analog of tryptophan) are
competitive inhibitors for indoleamine 2, 3-dioxygenase. Arch
Biochem Biophys. (1991) 291:326–33. doi: 10.1016/0003-9861(91)9
0142-6
2. Wirthgen E, Hoeflich A. Endotoxin-induced tryptophan degradation
along the kynurenine pathway: the role of indolamine 2, 3-dioxygenase
and aryl hydrocarbon receptor-mediated immunosuppressive
effects in endotoxin tolerance and cancer and its implications for
immunoparalysis. J Amino Acids. (2015) 2015:973548. doi: 10.1155/2015/9
73548
3. Wirthgen E, Hoeflich A, Rebl A, Günther J. Kynurenic acid: the
janus-faced role of an immunomodulatory tryptophan metabolite
and its link to pathological conditions. Front Immunol. (2018) 8:1957.
doi: 10.3389/fimmu.2017.01957
4. Ramos-Chávez LA, Lugo Huitrón R, González Esquivel D, Pineda B, Ríos
C, Silva-Adaya D, et al. Relevance of alternative routes of kynurenic acid
production in the brain. Oxid Med Cell Longev. (2018) 2018:5272741.
doi: 10.1155/2018/5272741
5. Jia L, Schweikart K, Tomaszewski J, Page JG, Noker PE, Buhrow SA,
et al. Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of
toxicity due to saturating absorption. Food Chem Toxicol. (2008) 46:203–11.
doi: 10.1016/j.fct.2007.07.017
6. Liu X, Newton RC, Friedman SM, Scherle PA. Indoleamine 2,
3-dioxygenase, an emerging target for anti-cancer therapy. Curr
Frontiers in Immunology | www.frontiersin.org 7 February 2020 | Volume 11 | Article 313
Wirthgen et al. 1-MT Induced a Shift to KYNA
Cancer Drug Targets. (2009) 9:938–52. doi: 10.2174/1568009097901
92374
7. Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, et al.
Evidence for a tumoral immune resistance mechanism based on tryptophan
degradation by indoleamine 2, 3-dioxygenase. Nat Med. (2003) 9:1269–74.
doi: 10.1038/nm934
8. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC.
Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of
the cancer suppression gene Bin1, potentiates cancer chemotherapy.Nat Med.
(2005) 11:312–9. doi: 10.1038/nm1196
9. Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, et al.
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers
of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res.
(2007) 67:792–801. doi: 10.1158/0008-5472.CAN-06-2925
10. Kiank C, Zeden J-P, Drude S, Domanska G, Fusch G, Otten W,
et al. Psychological stress-induced, IDO1-dependent tryptophan catabolism:
implications on immunosuppression in mice and humans. PLoS ONE. (2010)
5:e11825. doi: 10.1371/journal.pone.0011825
11. Wirthgen E, Otten W, Tuchscherer M, Tuchscherer A, Domanska G,
Brenmoehl J, et al. Effects of 1-methyltryptophan on immune responses and
the kynurenine pathway after lipopolysaccharide challenge in pigs. Int J Mol
Sci. (2018) 19:3009. doi: 10.3390/ijms19103009
12. Löb S, Königsrainer A, Zieker D, Brücher BL, Rammensee H-G, Opelz
G, et al. IDO1 and IDO2 are expressed in human tumors: levo-but not
dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol
Immunother. (2009) 58:153–7. doi: 10.1007/s00262-008-0513-6
13. Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, et al. Selective
inhibition of IDO1 effectively regulates mediators of antitumor immunity.
(2010) 115:3520–30. doi: 10.1182/blood-2009-09-246124
14. Fox E, Oliver T, RoweM, Thomas S, Zakharia Y, Gilman PB, et al. Indoximod:
an immunometabolic adjuvant that empowers T cell activity in cancer. Front
Oncol. (2018) 8:370. doi: 10.3389/fonc.2018.00370
15. Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop
L, Metz R, et al. Indoleamine 2,3-dioxygenase pathways of pathogenic
inflammation and immune escape in cancer. Cancer Immunol Immunother
CII. (2014) 63:721–35. doi: 10.1007/s00262-014-1549-4
16. Günther J, Däbritz J, Wirthgen E. Limitations and off-target effects of
tryptophan-related IDO inhibitors in cancer treatment. Front Immunol.
(2019) 10:1801. doi: 10.3389/fimmu.2019.01801
17. Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J, Tian H, et al.
Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J
Biol Chem. (2006) 281:22021–8. doi: 10.1074/jbc.M603503200
18. DiNatale BC, Murray IA, Schroeder JC, Flaveny CA, Lahoti TS,
Laurenzana EM, et al. Kynurenic acid is a potent endogenous aryl
hydrocarbon receptor ligand that synergistically induces interleukin-6
in the presence of inflammatory signaling. Toxicol Sci. (2010) 115:89–97.
doi: 10.1093/toxsci/kfq024
19. Steiner L, GoldM,Mengel D, Dodel R, Bach J-P. The endogenous α7 nicotinic
acetylcholine receptor antagonist kynurenic acid modulates amyloid-β-
induced inflammation in BV-2 microglial cells. J Neurol Sci. (2014) 344:94–9.
doi: 10.1016/j.jns.2014.06.032
20. Tiszlavicz Z, Németh B, Fülöp F, Vécsei L, Tápai K, Ocsovszky I, et al.
Different inhibitory effects of kynurenic acid and a novel kynurenic acid
analogue on tumour necrosis factor-α (TNF-α) production by mononuclear
cells, HMGB1 production by monocytes and HNP1-3 secretion by
neutrophils. Naunyn Schmiedeberg’s Arch Pharmacol. (2011) 383:447–55.
doi: 10.1007/s00210-011-0605-2
21. Mándi Y, Endrész V, Mosolygó T, Burián K, Lantos I, Fülöp F, et al. The
opposite effects of kynurenic acid and different kynurenic acid analogs on
tumor necrosis factor-α (TNF-α) production and tumor necrosis factor-
stimulated gene-6 (TSG-6) expression. Front Immunol. (2019) 10:1406.
doi: 10.3389/fimmu.2019.01406
22. Moroni F, Cozzi A, Sili M, Mannaioni G. Kynurenic acid: a metabolite with
multiple actions and multiple targets in brain and periphery. J Neural Transm.
(2012) 119:133–9. doi: 10.1007/s00702-011-0763-x
23. Elizei SS, Poormasjedi-Meibod M-S, Wang X, Kheirandish M, Ghahary A.
Kynurenic acid downregulates IL-17/1L-23 axis in vitro. Mol Cell Biochem.
(2017) 431:55–65. doi: 10.1007/s11010-017-2975-3
24. Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis:
from mechanisms to therapeutic testing. Nat Rev Immunol. (2014) 14:585.
doi: 10.1038/nri3707
25. Moroni F, Fossati S, Chiarugi A, Cozzi A (editors). Kynurenic acid actions in
brain and periphery. In: International Congress Series. Elsevier (2007).
26. Małaczewska J, Siwicki AK, Wójcik RM, Turski WA, Kaczorek E. The
effect of kynurenic acid on the synthesis of selected cytokines by murine
splenocytes - in vitro and ex vivo studies. Cent Eur J Immunol. (2016)
41:39–46. doi: 10.5114/ceji.2016.58815
27. Baban B, Chandler P, McCool D, Marshall B, Munn DH, Mellor AL.
Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant
cells during murine gestation and is maternal genome specific. J Reprod
Immunol. (2004) 61:67–77. doi: 10.1016/j.jri.2003.11.003
28. Wirthgen E, Tuchscherer M, Otten W, Domanska G, Wollenhaupt
K, Tuchscherer A, et al. Activation of indoleamine 2, 3-dioxygenase
by LPS in a porcine model. Innate Immun. (2014) 20:30–9.
doi: 10.1177/1753425913481252
29. Wirthgen E, Kanitz E, Tuchscherer M, Tuchscherer A, Domanska G,
Weitschies W, et al. Pharmacokinetics of 1-methyl-L-tryptophan after single
and repeated subcutaneous application in a porcine model. Exp Anim. (2016)
65:147–55. doi: 10.1538/expanim.15-0096
30. Suzuki Y, Suda T, Asada K, Miwa S, Suzuki M, Fujie M, et al.
Serum indoleamine 2,3-dioxygenase activity predicts prognosis of
pulmonary tuberculosis. Clin Vaccine Immunol CVI. (2012) 19:436–42.
doi: 10.1128/CVI.05402-11
31. Schmidt SK, Siepmann S, Kuhlmann K, Meyer HE, Metzger S, Pudelko
S, et al. Influence of tryptophan contained in 1-Methyl-Tryptophan
on antimicrobial and immunoregulatory functions of indoleamine 2,3-
dioxygenase. PLoS ONE. (2012) 7:e44797. doi: 10.1371/journal.pone.00
44797
32. Kanai M, Nakamura T, Funakoshi H. Identification and characterization of
novel variants of the tryptophan 2, 3-dioxygenase gene: differential regulation
in the mouse nervous system during development. Neurosci Res. (2009)
64:111–7. doi: 10.1016/j.neures.2009.02.004
33. Metz R, Rust S, DuHadaway JB, Mautino MR, Munn DH, Vahanian NN, et al.
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel
IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology.
(2012) 1:1460–8. doi: 10.4161/onci.21716
34. Stracke J, Otten W, Tuchscherer A, Witthahn M, Metges CC, Puppe B, et al.
Dietary tryptophan supplementation and affective state in pigs. J Vet Behav.
(2017) 20:82–90. doi: 10.1016/j.jveb.2017.03.009
35. Kleimeier D, Domanska G, Kanitz E, Otten W, Wirthgen E, Bröker BM, et al.
Effects of 1-Methyltryptophan on the kynurenine pathway in pigs. In: 5th
International Symposium Systems Biology of Microbial Infection. Jena (2019).
36. Han Q, Cai T, Tagle DA, Robinson H, Li J. Substrate specificity
and structure of human aminoadipate aminotransferase/kynurenine
aminotransferase II. Biosci Rep. (2008) 28:205–15. doi: 10.1042/BSR200
80085
37. Put K, Brisse E, Avau A, Imbrechts M, Mitera T, Janssens R, et al. IDO1
deficiency does not affect disease in mouse models of systemic juvenile
idiopathic arthritis and secondary hemophagocytic lymphohistiocytosis. PLoS
ONE. (2016) 11:e0150075. doi: 10.1371/journal.pone.0150075
38. Divanovic S, Sawtell NM, Trompette A, Warning JI, Dias A, Cooper
AM, et al. Opposing biological functions of tryptophan catabolizing
enzymes during intracellular infection. J Infect Dis. (2012) 205:152–61.
doi: 10.1093/infdis/jir621
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Wirthgen, Leonard, Scharf and Domanska. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Immunology | www.frontiersin.org 8 February 2020 | Volume 11 | Article 313
